



# *Daily Derivatives*

07 January, 2026

DERIVATIVES

07 January 2026

## Key Indices

Index	Close	Changes (%)
NIFTY	26178.70	-0.27
SENSEX	85063.34	-0.44
BANKNIFTY	60118.40	0.12
INDIA VIX	10.01	-0.05

## Market Outlook

The Nifty 50 ended the session at 26,178, registering a lacklustre and range-bound performance on the first weekly expiry of the January series. On the upside, profit taking was observed near the 26,300 level, while on the downside, the index found support and rebounded from the 26,100 mark. In the derivatives segment for the upcoming weekly expiry, fresh Call OI buildup at the 26,200 strike indicates that sustaining below this level may continue to cap the upside. On the downside, significant Put OI at the 26,000 strike provides immediate support, while a decisive break below this level could shift focus towards the 25,700 zone, which has previously acted as a strong base.



## TRADE IDEA OF THE DAY - ASIANPAINT

**BUY 27JAN 2840 CE**  
**SELL 27JAN 2920 CE**

Entry Range	29-31
Target Range	70
Stop Loss	10



## Rationale

- The stock price are currently trading above the key moving averages of 20-DEMA and 50-DEMA, indicating a resumption of short-term and medium-term bullish momentum after a healthy consolidation.
- On the daily chart a sustained breakout has been witnessed from the “22-Day high”, indicating fresh bullish momentum for the coming sessions
- The recent price action with the series of higher lows near the 2,750–2,780 zone highlights strong demand and confirms a solid base, along with this RSI is placed around the 55–60 zone, reflecting improvement in prevailing trend.
- MACD histogram are showing signs of a positive crossover with momentum stabilizing, suggesting continuation of the upward trend towards 2,920–2,950 levels.

07 January 2026

# Daily Derivatives


## NIFTY

Nifty	26281.90
OI (In Lots)	219579
CHANGE IN OI (%)	3.08
PRICE CHANGE (%)	-0.19


## BANKNIFTY

Nifty	60320.00
OI (In Lots)	49146
CHANGE IN OI (%)	10.28
PRICE CHANGE (%)	0.24


## NIFTY OI



## BANKNIFTY OI



## FIIs Activity Index Futures



## FIIs Long Short Ratio



## Long Buildup

Name	Price	Price %	OI	OI%
IEX	147.4	9.11	73672500	26.99
HAVELLS	1511.1	3.65	8362500	10.97
POLYCAB	7830.5	0.46	3150375	8.93
PHOENIXLTD	1953.1	0.71	3388350	8.56

## Short Buildup

Name	Price	Price %	OI	OI%
SWIGGY	364.8	-3.96	15923700	91.87
PREMIERENE	762.9	-3.39	2970450	43.22
WAAREEENER	2642	-2.50	2189250	33.34
TRENT	4069.3	-8.51	9845500	23.90

## Breakout Stocks (1 Month High)

Name	LTP	22 DAY HIGH	%
NATIONALUM	347.6	335.45	3.62
HAVELLS	1508.4	1467.5	2.79
IIFL	668.75	651.25	2.69
FORTIS	947.5	929	1.99

## Breakdown Stocks (1 Month Low)

Name	LTP	22 DAY LOW	%
CUMMINSIND	4151.3	4297.7	-3.41
HDFCBANK	966.95	978.95	-1.23
ITC	344.2	346.8	-0.75
POLICYBZR	1748.8	1762	-0.75

07 January 2026

# Daily Derivatives

## NIFTY 50 - STOCKS KEY LEVELS

SYMBOL	R1*	R2*	PP*	S1*	S2*
ADANIENT	2284	2308	2266	2241	2224
ADANIPTS	1487	1501	1479	1465	1457
APOLLOHOSP	7459	7569	7249	7139	6929
ASIANPAINT	2859	2872	2835	2822	2798
AXISBANK	1304	1314	1295	1285	1275
BAJAJ-AUTO	9782	9903	9663	9542	9422
BAJAJFINSV	2071	2097	2056	2030	2015
BAJFINANCE	985	993	979	971	966
BEL	416	419	413	410	408
BHARTIARTL	2122	2139	2105	2088	2071
CIPLA	1540	1550	1530	1521	1510
COALINDIA	431	434	428	424	421
DRREDDY	1262	1267	1254	1248	1240
EICHERMOT	7566	7610	7525	7482	7441
ETERNAL	283	287	280	276	272
GRASIM	2882	2898	2864	2847	2829
HCLTECH	1629	1642	1613	1600	1585
HDFCBANK	967	972	962	957	951
HDFCLIFE	787	796	771	761	745
HINDALCO	963	984	950	929	915
HINDUNILVR	2446	2467	2407	2386	2347
ICICIBANK	1428	1445	1397	1380	1349
INDIGO	5099	5195	5044	4948	4894
INFY	1622	1631	1610	1601	1589
ITC	350	357	344	337	331

\*R1 - Resistance 1 | \*R2 - Resistance 2 | \*PP - Pivot Point | \*S1 - Support 1 | \*S2 - Support 2

07 January 2026

*Daily*  
**Derivatives**

## NIFTY 50 - STOCKS KEY LEVELS

SYMBOL	R1*	R2*	PP*	S1*	S2*
JIOFIN	303	307	298	294	289
JSWSTEEL	1193	1210	1181	1164	1152
KOTAKBANK	2205	2263	2170	2112	2077
LT	4174	4207	4152	4119	4097
M&M	3817	3849	3788	3756	3727
MARUTI	17351	17411	17247	17187	17083
MAXHEALTH	1061	1071	1052	1043	1034
NESTLEIND	1329	1339	1314	1304	1289
NTPC	355	358	350	347	342
ONGC	243	245	241	239	237
POWERGRID	273	277	269	265	262
RELIANCE	1552	1597	1524	1480	1452
SBILIFE	2113	2131	2089	2071	2047
SBIN	1027	1035	1016	1008	997
SHRIRAMFIN	1012	1022	1002	993	983
SUNPHARMA	1773	1786	1750	1736	1713
TATACONSUM	1223	1235	1203	1190	1170
TATASTEEL	188	190	186	185	183
TCS	3278	3300	3241	3219	3183
TECHM	1619	1637	1608	1590	1578
TITAN	4132	4152	4100	4080	4048
TMPV	374	378	367	362	355
TRENT	4173	4298	4083	3958	3869
ULTRACEMCO	12264	12324	12165	12105	12006
WIPRO	267	268	265	264	262

\*R1 - Resistance 1 | \*R2 - Resistance 2 | \*PP - Pivot Point | \*S1 - Support 1 | \*S2 - Support 2

**Our Research Team**

Name	Email ID
Ajit Mishra	<a href="mailto:ajit.mishra@religare.com">ajit.mishra@religare.com</a>
Abhijeet Banerjee	<a href="mailto:abhijeet.banerjee@religare.com">abhijeet.banerjee@religare.com</a>
Gaurav Sharma	<a href="mailto:gauravsharma2@religare.com">gauravsharma2@religare.com</a>
Ashwani Harit	<a href="mailto:ashwani.harit@religare.com">ashwani.harit@religare.com</a>
Divya Parmar	<a href="mailto:divya.parmar@religare.com">divya.parmar@religare.com</a>
Rajan Gupta	<a href="mailto:rajan.gupta1@religare.com">rajan.gupta1@religare.com</a>
Vivek Chandra	<a href="mailto:vivek.chandra@religare.com">vivek.chandra@religare.com</a>
Himanshu Gupta	<a href="mailto:himanshu.gupta1@religare.com">himanshu.gupta1@religare.com</a>

07 January 2026

# Daily Derivatives

Before you use this research report, please ensure to go through the disclosure interalia as required under Securities and Exchange Board of India (Research Analysts) Regulations, 2014 and Research Disclaimer at the following link: [www.religareonline.com/disclaimer](http://www.religareonline.com/disclaimer)

Specific analyst(s) specific disclosure(s) inter-alia as required under Securities and Exchange Board of India (Research Analysts) Regulations, 2014 is/are as under:

S.No.	Statement	Answer	
		Tick Appropriate	
		Yes	No
1.	I/we or any of my/our relative has any financial interest in the subject company? (If answer is yes, nature of interest is given below this table)		No
2.	I/we or any of my/our relatives, have actual/beneficial ownership of one per cent. or more securities of the subject company, at the end of the month immediately preceding the date of the research report or date of the public appearance?		No
3.	I/we or any of my/our relative, has any other material conflict of interest at the time of publication of the research report or at the time of the public appearance?		
4.	I/we have received any compensation from the subject company in the past twelve months?		No
5.	I/we have managed or co-managed public offering of securities for the subject company in the past twelve months?		No
6.	I/we have received any compensation for brokerage services from the subject company in the past twelve months?		No
7.	I/we have received any compensation or other benefits from the subject company or third party in connection with the research report?		No
8.	I/we have served as an officer, director or employee of the subject company?		No
9.	I/we have been engaged in market making activity for the subject company?		No

2014 is/are as under:

Statements of ownership and material conflicts of interest, compensation – Research Analyst (RA)

Nature of Interest [If answer to f (a) above conflicts is Yes

.....]

Name(s) with Signature(s) of RA(s).

[Please note that only in case of multiple RAs and if the answers differ inter-se between the RAs, then RA specific answer with respect to

**Copyright:** This document vests exclusively with RBL. This information should not be reproduced or redistributed or passed on directly or indirectly in any form to any other person or published, copied, in whole or in part, for any purpose, without prior written permission from RBL. We do not guarantee the integrity of any emails or attached files and are not responsible for any changes made to them by any other person.